These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 31445426)
1. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Brusselaers N; Lagergren J; Engstrand L Cancer Epidemiol; 2019 Oct; 62():101585. PubMed ID: 31445426 [TBL] [Abstract][Full Text] [Related]
2. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Brusselaers N; Engstrand L; Lagergren J Cancer Epidemiol; 2018 Apr; 53():172-177. PubMed ID: 29477057 [TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. Brusselaers N; Wahlin K; Engstrand L; Lagergren J BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798 [TBL] [Abstract][Full Text] [Related]
4. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. García Rodríguez LA; Lagergren J; Lindblad M Gut; 2006 Nov; 55(11):1538-44. PubMed ID: 16785284 [TBL] [Abstract][Full Text] [Related]
5. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy. Holmberg D; Mattsson F; Xie S; Ness-Jensen E; El-Serag H; Lagergren J J Gastroenterol; 2022 Dec; 57(12):942-951. PubMed ID: 36258093 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Chandanos E; Lindblad M; Jia C; Rubio CA; Ye W; Lagergren J Br J Cancer; 2006 Jul; 95(1):118-22. PubMed ID: 16755290 [TBL] [Abstract][Full Text] [Related]
8. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Tran-Duy A; Spaetgens B; Hoes AW; de Wit NJ; Stehouwer CD Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1706-1719.e5. PubMed ID: 27211501 [TBL] [Abstract][Full Text] [Related]
9. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Cheung KS; Chan EW; Wong AYS; Chen L; Wong ICK; Leung WK Gut; 2018 Jan; 67(1):28-35. PubMed ID: 29089382 [TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380 [TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences. Waldum HL; Sørdal Ø; Fossmark R Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782 [TBL] [Abstract][Full Text] [Related]
12. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis. Peng TR; Wu TW; Li CH Int J Clin Oncol; 2023 Jan; 28(1):99-109. PubMed ID: 36224477 [TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286 [TBL] [Abstract][Full Text] [Related]
14. Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study. Kim JW; Jung HK; Lee B; Shin CM; Gong EJ; Hong J; Youn YH; Lee KJ Eur J Clin Pharmacol; 2023 Dec; 79(12):1699-1708. PubMed ID: 37861752 [TBL] [Abstract][Full Text] [Related]
15. Gastric carcinoids after long-term use of a proton pump inhibitor. Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200 [TBL] [Abstract][Full Text] [Related]
16. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. Jiang K; Jiang X; Wen Y; Liao L; Liu FB J Gastroenterol Hepatol; 2019 Nov; 34(11):1898-1905. PubMed ID: 31206764 [TBL] [Abstract][Full Text] [Related]
17. Intake of Proton-Pump Inhibitors and Gastric Cancer within the Stomach Cancer Pooling (StoP) Project. Sassano M; Mariani M; Pelucchi C; Lunet N; Morais S; Martín V; Moreno V; Curado MP; Dias-Neto E; Leja M; Gašenko E; La Vecchia C; Boccia S; Pastorino R Cancer Epidemiol Biomarkers Prev; 2023 Sep; 32(9):1174-1181. PubMed ID: 37364052 [TBL] [Abstract][Full Text] [Related]
18. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Vaughan TL; Farrow DC; Hansten PD; Chow WH; Gammon MD; Risch HA; Stanford JL; Schoenberg JB; Mayne ST; Rotterdam H; Dubrow R; Ahsan H; West AB; Blot WJ; Fraumeni JF Cancer Epidemiol Biomarkers Prev; 1998 Sep; 7(9):749-56. PubMed ID: 9752982 [TBL] [Abstract][Full Text] [Related]
19. Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. Colin-Jones DG; Langman MJ; Lawson DH; Logan RF; Paterson KR; Vessey MP Q J Med; 1991 Jan; 78(285):13-9. PubMed ID: 1670060 [TBL] [Abstract][Full Text] [Related]
20. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. Ye W; Nyrén O Gut; 2003 Jul; 52(7):938-41. PubMed ID: 12801947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]